Quinolone carboxylic acid-substituted rifamycin derivatives
View Patent ↗The compounds include substituted rifamycin derivatives in which a quinolone carboxylic acid pharmacophore is covalently bonded to a benzoxazinorifamycin or a spiropiperidinorifamycin. The rifamycin derivatives are useful as antimicrobial agents and are effective against a number of human and veterinary Gram positive and Gram negative pathogens. The advantage of the inventive compounds is that both the rifamycin and quinolone antibacterial pharmacophores are co-delivered with matched pharmacokinetics to the targeted pathogens of interests. Delivery of multiple antibacterial pharmacophores simultaneously to the targeted pathogens has the maximum chance of achieving synergy and minimizing the development of resistance to the antibiotics given.
1. A compound of structural formula (I):
or a pharmaceutically acceptable salt thereof,
wherein:
X 1 is NH, NR 4 , O or S;
X 2 is N or CR 5 ;
L is a bond, or a linker group selected from one or a combination of two to three of the following groups:
1) (C 1 -C 6 )alkylene,
2) (C 3 -C 8 )cycloalkylene,
3) arylene,
4) heteroarylene,
5) heterocycloalkylene containing 1 to 3 heteroatoms,
6) —C(═O)—,
7) —C(═N—O—R 6 )—,
8) —C═N—,
9) —O—,
10) —S(O) n —, wherein n is number between 0 and 2,
11) —N(R 7 )—,
wherein the carbon or nitrogen atoms of the linker “L” group are optionally substituted by 1 to 3 substituents selected from (C 1 -C 6 )alkyl, substituted (C 1 -C 6 )alkyl, amino, (C 1 -C 6 )alkylamino, di(C 1 -C 6 )alkylamino, hydroxyl, (C 1 -C 6 )alkoxy, and heterocycloalkyl group;
Q is N or CR 8 ;
Y and Z are independently selected from C or N;
R 1 is H or acetyl group;
R 2 , R 4 , R 5 , R 6 , R 7 are independently a group selected from hydrogen, (C 1 -C 6 )alkyl, (C 3 -C 7 )cycloalkyl, aryl, heteroaryl, and heterocycloalkyl groups that are all optionally substituted;
R 3 is H, —OH or —SH; and
R 8 is H, F, Cl, CN, CH 3 ,'OCH 3 , OCHF 2 or CF 3 .
2. The compound of claim 1 , wherein R 1 is acetyl group.
3. The compound of claim 1 , wherein L is a bond or one or a combination of two to five groups selected from:
wherein the combination does not contain consecutive heteroatoms.
4. A compound as defined by claim 1 selected from the following compounds:
a. (R)-5′-[3-{1-(4-{1-[1-(3-Carboxy-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-4H-quinolizine-8-yl)-pyrrolidin-3-yl-cyclopropyl]-methylamino}-piperidin-1-yl]-3′-hydroxy-benzoxazinorifamycin:
b. (R)-5′-[4-[1-[1-(3-Carboxy-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydro-quinoline-7-yl)-pyrrolidin-3-yl-cyclopropyl-methyl]-amino]-piperidin-1-yl]-3′-hydroxy-benzoxazinorifamycin:
c. 5′-[4-(3-Carboxy-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinolin-7-yl)-piperazin-1-yl]-3′-hydroxy-benzoxazinorifamycin:
d. 5′-[4-[1-(3-Carboxy-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydro-quinoline-7-yl)-piperidin-4-yl-amino]-piperidin-1-yl]-3′-hydroxy-benzoxazinorifamycin:
e. (R/S)-5′-[4-[[1-(1-Cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydro-quinolin-7-yl)-pyrrolidin-3-ylmethyl]-(2-dimethylamino-ethyl)-amino]-piperidin-1-yl]-3′-hydroxy-benzoxazinorifamycin:
f. 4-Deoxy-3,4-[2-spiro-[1-(3-carboxy-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinolin-7-yl)-piperidin-4-yl]]-(1H)-imidazo-(2,5-dihydro)rifamycin S:
g. 4-Deoxy-3,4-[2-spiro-[1-(3-carboxy-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinolin-7-yl)-piperidin-4-yl]]-(1H)-imidazo-(2,5-dihydro)rifamycin S:
h. (R/S)-4-Deoxy-3,4-[2-spiro-[1-[1-(3-carboxy-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinolin-7-yl)-pyrrolidin-3-methyl]-piperidin-4-yl]]-(1H)-imidazo-(2,5-dihydro)rifamycin S:
5. A pharmaceutical composition, useful as an antibacterial medicament, comprising a pharmaceutically effective amount of a compound in accordance with claim 1 in combination with a pharmaceutically acceptable carrier.
6. A method of treating a bacterial infection in a patient in need of such treatment by administering the pharmaceutical composition in accordance with claim 5 .